$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
WARREN, N.J., March 27, 2017 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced a poster presentation at the 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) which will take place in San Diego, CA, from April 5 to 8. The poster will feature data from an investigator-led study of INOpulse® in patients with pulmonary arterial hypertension (PAH).
| Title: | Effects of Ambulatory Inhaled Nitric Oxide on Exercise Induced Increases in Pulmonary Pressures | |
| Authors: | R. A. Davey (Division of Cardiology, Western University, London, ON), A. Raina, R. L. Benza (Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA) | |
| Date: | Thursday, April 6 | |
| Time: | 6:15 – 7:15 pm Pacific Time | |
| Session: | Poster Session 2 | |
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance (PVR) and subsequent reductions in cardiac output; these changes are further worsened by exercise. Inhaled nitric oxide (iNO) can decrease PVR and improve cardiac output in PAH patients.
In this study, the investigators looked at the effects of pulsed iNO on PVR and cardiac output in PAH patients with the CardioMEMS, an implantable hemodynamic monitoring device, both before and after exercise. Inhaled NO was delivered using Bellerophon’s proprietary INOpulse delivery system, that provides pulsed iNO in the ambulatory setting. The INOpulse delivery system is designed to be used chronically in outpatients and is currently in Phase 3 clinical trials for PAH.
About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. ISHLT was founded in 1981 and today has more than 3,400 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. The 37th Annual Meeting and Scientific Sessions will take place at the Manchester Grand Hyatt, San Diego, April 5 – 8. For more information, refer to http://www.ishlt.org/meetings/annualMeeting.asp.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contacts At Bellerophon: Fabian Tenenbaum, Chief Executive Officer (908) 574-4767 At LifeSci Advisors: Bob Yedid (646) 597-6989 [email protected]
